Bexepril 5mg Film-coated Tablet for Dogs

Maa: Yhdistynyt kuningaskunta

Kieli: englanti

Lähde: VMD (Veterinary Medicines Directorate)

Aktiivinen ainesosa:

Benazepril Hydrochloride

Saatavilla:

Chanelle Pharmaceuticals Manufacturing Ltd

ATC-koodi:

QC09AA07

INN (Kansainvälinen yleisnimi):

Benazepril Hydrochloride

Lääkemuoto:

Film-coated tablet

Prescription tyyppi:

POM-V - Prescription Only Medicine – Veterinarian

Terapeuttinen ryhmä:

Dogs

Terapeuttinen alue:

Cardio Vascular ACE inhibitor

Valtuutuksen tilan:

Expired

Valtuutus päivämäärä:

2010-04-23

Valmisteyhteenveto

Revised: June 2015
AN: 01657/2014
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Bexepril 5mg Film-coated tablet for dogs (BE & IE)
Bexepril 5mg Film-coated tablet for dogs (BG, CY, CZ, DK, EL, ES, HU,
LU, NL, NO,
PT, RO, SI, SK & UK)
Sirdis 5mg Film-coated tablet for dogs (IT)
Bexepril 5mg Film-coated tablets for dogs (PL)
Bexepril 5 Film-coated tablet for dogs (FR)
Bexepril l 5mg Film-coated tablet for dogs, Benazeprilhydochlorid (AT)
Benadog Flavour 5mg Film-coated tablets for dogs, Benzeprilhydochlorid
(DE)
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE:
Each tablet contains:
Benazepril 4.6mg
(equivalent to Benazepril Hydrochloride 5mg)
EXCIPIENT:
Titanium Dioxide (E171) 0.9348mg
Iron Oxide Yellow (E172) 0.0476mg
Quinoline Yellow Aluminum Lake (E104) 0.0176mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablets.
A round yellow biconvex tablet with break line on one side. The
tablets can be divided
into equal halves.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
In dogs weighing more than 10 kg:
Treatment of congestive heart failure associated with, in particular,
dilated
cardiomyopathy and/or mitral insufficiency.
4.3
CONTRAINDICATIONS
Do not use in any dog that has evidence of cardiac output failure due,
for example, to
aortic stenosis.
Do not use in animals known to be hypersensitive to the active
substance or to any of
the excipient(s).
See section 4.7.
Revised: June 2015
AN: 01657/2014
Page 2 of 5
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
No evidence of renal toxicity to the product has been observed in dogs
during clinical
trials. However, as is routine in cases of renal insufficiency, it is
recommended to
monitor plasma creatinine and urea during therapy.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
VETERINARY
MEDICINAL PRODUCT TO ANIMALS
Wash hands aft